This provides a chemical link between FGFR inhibitors and MAPK inhibitors (MEK), which have previously been documented as causing SRF in the treatment of systemic cancers as a specific disease entity, i.e., MEK-induced retinopathy (8–10). Here, MAP2K7 is linked to retinal disorder.